Back to EveryPatent.com
United States Patent |
5,512,559
|
Skalkos
,   et al.
|
April 30, 1996
|
Method of treating cancer tumors with imine porphyrin compounds
Abstract
Purified imines of porphyrins, chlorins, bateriochlorins, chlorophylls,
bacteriochlorophylls, purpurins, reduced purpurins, verdins, Diels Alder
adducts, benzochlorins and metal complexes of the foregoing imines are
disclosed. The formulas of the benzochlorinimines and of the
benzochlorinimine metal complexes are set forth below:
##STR1##
In specific examples, M in the metal complexes is a copper cation that is
complexed with two of the nitrogens of the benzochlorinimine R' and R""
are methyl, and R1 through R8 are ethyl.
Inventors:
|
Skalkos; Dimitris (Toledo, OH);
Selman; Steven H. (Toledo, OH);
Hampton; James A. (Waterville, OH)
|
Assignee:
|
The University of Toledo and Medical College of Ohio (Toledo, OH)
|
Appl. No.:
|
375629 |
Filed:
|
January 19, 1995 |
Current U.S. Class: |
514/185; 514/410; 534/11; 534/12; 540/145 |
Intern'l Class: |
A61K 031/40; C07D 487/22 |
Field of Search: |
514/185,410
540/145
|
References Cited
U.S. Patent Documents
5424305 | Jun., 1995 | Skalkos et al. | 514/185.
|
Primary Examiner: Shah; Mukund J.
Assistant Examiner: Sripada; Pavanaram K.
Attorney, Agent or Firm: Marshall & Melhorn
Parent Case Text
This application is a continuation of application Ser. No. 08/158,020,
filed Nov. 24, 1993 which is a continuation of application Ser. No.
07/901,597, filed Jun. 19, 1992 abandoned.
Claims
We claim:
1. As a cancer tumor treating method by means of photodynamic therapy with
composition of matter, a purified imine of a porphyrin, a chlorin, a
bacteriochlorin, a chlorophyll, a bacteriochlorophyll, a purpurin, a
reduced purpurin, a verdin, a Diels Alder adduct, an isobacteriochlorin, a
benzochlorin or a metal complex of one of the foregoing imines having one
of the structures set forth below, and identified by legend:
##STR19##
wherein M comprises a metal cation that is complexed with two of the
nitrogens of the benzochlorin and is Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Eu,
Fe, Ga, Gd, Hf, Ho, In, La, Lu, Mn, Mo, Nd, Pb, Pd, Pr, Pt, Rh, Sb, Sc,
Sm, Sn, Tb, .sup.99m Tc, Th, Ti, Tl, Tm, U, V, Y, Yb, Zn or Zr,
A is a physiologically acceptable anion,
R' and R" can be the same or different, and each is hydrogen or an alkyl
group having from one to four carbon atoms, and
each of R1 through R11 is
H or CHO,
an alkyl group other than t-butyl having from 1 to 4 atoms,
an alkylene group having from 2 to 4 carbon atoms,
a group having the formula R.sub.3 N (R.sub.4).sub.3 A where R.sub.3 is a
bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms,
wherein any carbon to carbon bond is either a single or a double bond, and
not more than one is a double bond; R.sub.4 is hydrogen or an alkyl
radical having 1 to 2 carbon atoms and the two R.sub.4 groups can be the
same or different,
a group having the formula R.sub.3 N (R.sub.5).sub.3 A where R.sub.3 is a
bivalent hydrocarbon radical having from 1 to 4 carbon atoms, wherein any
carbon to carbon bond is either a single or a double bond, and not more
than one is a double bond; A is a physiologically acceptable anion and
R.sub.5 is an alkyl group having from 1 to 2 carbon atoms and the three
R.sub.5 groups can be the same or different,
a group having the formula R.sub.3 OH where R.sub.3 is a bivalent aliphatic
hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to
carbon bond is either a single or a double bond, and not more than one is
a double bond, or
CO.sub.2 R', CH.sub.2 CO.sub.2 R' or CH.sub.2 CH.sub.2 CO.sub.2 R' where R'
is H, or an alkyl group other than t-butyl having from one to four carbon
atoms, with the provisos that R11 can be SO.sub.3 H or a salt thereof,
that, in the foregoing chlorinimines and metal complexes, either R3 or R4
can be a CH.sub.2 group or O which, in either case, is bonded to the
carbon of the pyrrole ring by a double bond, that, in the foregoing
families of compounds which are designated Isobacteriochlorinimines I and
Isobacteriochlorinimines II and their metal complexes, either R1 or R2 can
be a CH2 group or O which, in either case, is bonded to the carbon of the
pyrrole ring by a double bond and, when either R1 or R2 is a CH.sub.2
group or O, either R3 or R4 is also a CH.sub.2 group or O which is bonded
to the carbon of the pyrrole ring by and double bond, and that in the
foregoing families of compounds which are designated bacteriochlorinimines
and metal complexes, either R3 or R4 can be a CH.sub.2 group or O which,
in either case, is bonded to the carbon of the pyrrole ring by a double
bond and, when either R3 or R4 is a CH.sub.2 group or O, either R7 or R8
is also a CH.sub.2 group or O which is bonded to the carbon of the pyrrole
ring by and double bond.
2. A method for treating a human or animal patient which comprises
administering an effective amount of a benzochlorin having the structure
of Formula III or of a metal complex of a benzochlorin having the
structure of Formula IV, below:
##STR20##
wherein M comprises a metal cation that is complexed with two of the
nitrogens of the benzochlorin and is Cu, Fe or Ni,
R.sub.1 and R.sub.2 can be the same or different and each is an alkyl group
other than t-butyl having from 1 to 4 carbon atoms, and
each of R1 through R11 is
H or CHO,
an alkyl group other than 1-butyl having from 1 to 4 carbon atoms,
an alkylene group having from 2 to 4 carbon atoms,
a group having the formula R.sub.3 N(R.sub.4).sub.2 where R.sub.3 is a
bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms,
wherein any carbon to carbon bond is either a single or a double bond, and
not more than one is a double bond; R.sub.4 is hydrogen or an alkyl
radical having from 1 to 2 carbon atoms and the two R.sub.4 groups can be
the same or different,
a group having the formula R.sub.3 N(R.sub.5).sub.3 A where R.sub.3 is a
bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms,
wherein any carbon to carbon bond is either a single or a double bond, and
not more than one is a double bond; A is a physiologically acceptable
anion and R.sub.5 is an alkyl group having from 1 to 2 carbon atoms and
the three R.sub.5 groups can be the same or different,
a group having the formula R.sub.3 OH where R.sub.3 is a bivalent aliphatic
hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to
carbon bond is either a single or a double bond, and not more than one is
a double bond, or
CO.sub.2 R', CH.sub.2 CO.sub.2 R' or CH.sub.2 CH.sub.2 CO.sub.2 R' where R'
is H, or an alkyl group other than t-butyl having from one to four carbon
atoms,
with the proviso that R11 can be SO.sub.3 H or a salt thereof, and
irradiating the patient with pulsed excitation at a suitable wavelength
and of sufficient intensity to promote residual benzochlorin or
benzochlorin metal complex in the patient to the singlet state.
3. A method as claimed in claim 2 which comprises administering a
benzochlorin metal complex wherein each of R9 through R11 is hydrogen,
each of R1 through R8 is an alkyl group other than t-butyl having from 1
to 4 carbon atoms, and M is Ni.
4. A method of retarding growth of cancer tumors by means of photodynamic
therapy using a benzochlorin metal complex as claimed in claim 1 wherein
each of R9 through R11 is hydrogen, each of R1 through R8 is an alkyl
group other than t-butyl having from 1 to 4 carbon atoms, and M is Cu.
5. A cancer tumor treating method using a composition consisting
essentially of a solution in a solvent of a benzochlorin having the
structure of Formula III or a metal complex of a benzochlorin having the
structure of Formula IV, below:
##STR21##
wherein M comprises a metal cation that is complexed with two of the
nitrogens of the benzochlorin and is Cu, Fe or Sn,
R.sub.1 and R2 can be the same or different and each is an alkyl group
other than t-butyl having from 1 to 4 carbon atoms, and
each of R1 through R11 is
H or CHO
an alkyl group other than t-butyl having from 1 to 4 carbon atoms,
an alkylene group having from 2 to 4 carbon atoms,
a group having the formula R.sub.3 N(R.sub.4).sub.2 where R.sub.3 is a
bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms,
wherein any carbon to carbon bond is either a single or a double bond, and
not more than one is a double bond; R.sub.4 is hydrogen or an alkyl
radical having from 1 to 2 carbon atoms and the two R.sub.4 groups can be
the same or different,
a group having the formula R.sub.3 N(R.sub.5).sub.3 A where R.sub.3 is a
bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms,
wherein any carbon to carbon bond is either a single or a double bond, and
not more than one is a double bond; A is a physiologically acceptable
anion and R.sub.5 is an alkyl group having from 1 to 2 carbon atoms and
the three R.sub.5 groups can be the same or different,
a group having the formula R.sub.3 OH where R.sub.3 is a bivalent aliphatic
hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to
carbon bond is either a single or a double bond, and not more than one is
a double bond, or
CO.sub.2 R', CH.sub.2 CO.sub.2 R' or CH.sub.2 CH.sub.2 CO.sub.2 R' where R'
is H, or an alkyl group other than t-butyl having from one to four carbon
atoms, with the proviso that R11 can be SO.sub.3 H or a salt thereof, and
wherein the solution comprises an organic liquid equivalent to an
ethylene/fatty acid reaction product solubilizer, and is one which is
physiologically acceptable and of a suitable concentration or dilutable to
a suitable concentration for intravenous administration.
6. A method of using a solution of a benzochlorin metal complex as claimed
in claim 1 wherein each of R9 through R11 is hydrogen, each of R1 through
R8 is an alkyl group other than t-butyl having from 1 to 4 carbon atoms,
and M is Cu.
7. A method as defined in claim 1 in which there is an aqueous emulsion or
suspension of a solution of a benzochlorin or a benzochlorin metal
complex.
8. A method as defined in claim 1 in which the amount of the complex is
equivalent to about 3.5 to 7 mg/kg of body weight of a patient.
9. A method as defined in claim 8 in which the amount of copper complex is
about 3.5 mg/kg.
10. A method of dissolving plaques in blood vessels using photodynamic
therapy with a composition of matter, a purified imine of a porphyrin, a
chlorin, a bacteriochlorin, a chlorophyll, a bacteriochlorophyll, a
purpurin, a reduced purpurin, a verdin, a Diels Alder adduct, an
isobacteriochlorin, a benzochlorin or a metal complex of one of the
foregoing imines having one of the structures set forth below, and
identified by legend:
##STR22##
wherein M comprises a metal cation that is complexed with two of the
nitrogens of the benzochlorin and is Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Eu,
Fe, Ga, Gd, Hf, Ho, In, La, Lu, Mn, Mo, Nd, Pb, Pd, Pr, Pt, Rh, Sb, Sc,
Sm, Sn, Tb, .sup.99m Tc, Th, Ti, Tl, Tm, U, V, Y, Yb, Zn or Zr,
A is a physiologically acceptable anion,
R' and R" can be the same or different, and each is hydrogen or an alkyl
group having from one to four carbon atoms, and
each of R1 through R11 is
H or CHO,
an alkyl group other than t-butyl having from 1 to 4 atoms,
an alkylene group having from 2 to 4 carbon atoms,
a group having the formula R.sub.3 N(R.sub.4).sub.3 A where R.sub.3 is a
bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms,
wherein any carbon to carbon bond is either a single or a double bond, and
not more than one is a double bond; R.sub.4 is hydrogen or an alkyl
radical having 1 to 2 carbon atoms and the two R.sub.4 groups can be the
same or different,
a group having the formula R.sub.3 N(R.sub.5).sub.3 A where R.sub.3 is a
bivalent hydrocarbon radical having from 1 to 4 carbon atoms, wherein any
carbon to carbon bond is either a single or a double bond, and not more
than one is a double bond; A is a physiologically acceptable anion and
R.sub.5 is an alkyl group having from 1 to 2 carbon atoms and the three
R.sub.5 groups can be the same or different.
a group having the formula R.sub.3 OH where R.sub.3 is a bivalent aliphatic
hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to
carbon bond is either a single or a double bond, and not more than one is
a double bond, or
CO.sub.2 R', CH.sub.2 CO.sub.2 R' or CH.sub.2 CH.sub.2 CO.sub.2 R' where R'
is H, or an alkyl group other than t-butyl having from one to four carbon
atoms, with the provisos that R11 can be SO.sub.3 H or a salt thereof,
that, in the foregoing chlorinimines and metal complexes, either R3 or R4
can be a CH.sub.2 group or O which, in either case, is bonded to the
carbon of the pyrrole ring by a double bond, that, in the foregoing
families of compounds which are designated Isobacteriochlorinimines I and
Isobacteriochlorinimines II and their metal complexes, either R1 or R2 can
be a CH2 group or O which, in either case, is bonded to the carbon of the
pyrrole ring by a double bond and, when either R1 or R2 is a CH.sub.2
group or O, either R3 or R4 is also a CH.sub.2 group or O which is bonded
to the carbon of the pyrrole ring by and double bond, and that in the
foregoing families of compounds which are designated bacteriochlorinimines
and metal complexes, either R3 or R4 can be a CH.sub.2 group or O which,
in either case, is bonded to the carbon of the pyrrole ring by a double
bond and, when either R3 or R4 is a CH.sub.2 group or O, either R7 or R8
is also a CH.sub.2 group or O which is bonded to the carbon of the pyrrole
ring by and double bond.
11. A method of treating topical skin conditions using photodynamic therapy
with a composition of matter, a purified imine of a porphyrin, a chlorin,
a bacteriochlorin, a chlorophyll, a bacteriochlorophyll, a purpurin, a
reduced purpurin, a verdin, a Diels Alder adduct, an isobacteriochlorin, a
benzochlorin or a metal complex of one of the foregoing imines having one
of the structures set forth below, and identified by legend:
##STR23##
wherein M comprises a metal cation that is complexed with two of the
nitrogens of the benzochlorin and is Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Eu,
Fe, Ga, Gd, Hf, Ho, In, La, Lu, Mn, Mo, Nd, Pb, Pd, Pr, Pt, Rh, Sb, Sc,
Sm, Sn, Tb, .sup.99m Tc, Th, Ti, Tl, Tm, U, V, Y, Yb, Zn or Zr,
A is a physiologically acceptable anion,
R' and R" can be the same or different, and each is hydrogen or an alkyl
group having from one to four carbon atoms, and
each of R1 through R11 is
H or CHO,
an alkyl group other than t-butyl having from 1 to 4 atoms,
an alkylene group having from 2 to 4 carbon atoms,
a group having the formula R.sub.3 N(R.sub.4).sub.3 A where R.sub.3 is a
bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms,
wherein any carbon to carbon bond is either a single or a double bond, and
not more than one is a double bond; R.sub.4 is hydrogen or an alkyl
radical having 1 to 2 carbon atoms and the two R.sub.4 groups can be the
same or different,
a group having the formula R.sub.3 N(R.sub.5).sub.3 A where R.sub.3 is a
bivalent hydrocarbon radical having from 1 to 4 carbon atoms, wherein any
carbon to carbon bond is either a single or a double bond, and not more
than one is a double bond; A is a physiologically acceptable anion and
R.sub.5 is an alkyl group having from 1 to 2 carbon atoms and the three
R.sub.5 groups can be the same or different,
a group having the formula R.sub.3 OH where R.sub.3 is a bivalent aliphatic
hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to
carbon bond is either a single or a double bond, and not more than one is
a double bond, or
CO.sub.2 R', CH.sub.2 CO.sub.2 R' or CH.sub.2 CH.sub.2 CO.sub.2 R' where R'
is H, or an alkyl group other than t-butyl having from one to four carbon
atoms, with the provisos that R11 can be SO.sub.3 H or a salt thereof,
that, in the foregoing chlorinimines and metal complexes, either R3 or R4
can be a CH.sub.2 group or O which, in either case, is bonded to the
carbon of the pyrrole ring by a double bond, that, in the foregoing
families of compounds which are designated Isobacteriochlorinimines I and
Isobacteriochlorinimines II and their metal complexes, either R1 or R2 can
be a CH2 group or O which, in either case, is bonded to the carbon of the
pyrrole ring by a double bond and, when either R1 or R2 is a CH.sub.2
group or O, either R3 or R4 is also a CH.sub.2 group or O which is bonded
to the carbon of the pyrrole ring by and double bond, and that in the
foregoing families of compounds which are designated bacteriochlorinimines
and metal complexes, either R3 or R4 can be a CH.sub.2 group or O which,
in either case, is bonded to the carbon of the pyrrole ring by a double
bond and, when either R3 or R4 is a CH.sub.2 group or O, either R7 or R8
is also a CH.sub.2 group or O which is bonded to the carbon of the pyrrole
ring by and double bond.
12. A method of sterilizing blood using photodynamic therapy with a
composition of matter, a purified imine of a porphyrin, a chlorin, a
bacteriochlorin, a chlorophyll, a bacteriochlorophyll, a purpurin, a
reduced purpurin, a verdin, a Diels Alder adduct, an isobacteriochlorin, a
benzochlorin or a metal complex of one of the foregoing imines having one
of the structures set forth below, and identified by legend:
##STR24##
wherein M comprises a metal cation that is complexed with two of the
nitrogens of the benzochlorin and is Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Eu,
Fe, Ga, Gd, Hf, Ho, In, La, Lu, Mn, Mo, Nd, Pb, Pd, Pr, Pt, Rh, Sb, Sc,
Sm, Sn, Tb, .sup.99m Tc, Th, Ti, Tl, Tm, U, V, Y, Yb, Zn or Zr,
A is a physiologically acceptable anion,
R' and R" can be the same or different, and each is hydrogen or an alkyl
group having from one to four carbon atoms, and
each of R1 through R11 is
H or CHO,
an alkyl group other than t-butyl having from 1 to 4 atoms,
an alkylene group having from 2 to 4 carbon atoms,
a group having the formula R.sub.3 N (R.sub.4).sub.3 A where R.sub.3 is a
bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms,
wherein any carbon to carbon bond is either a single or a double bond, and
not more than one is a double bond; R.sub.4 is hydrogen or an alkyl
radical having 1 to 2 carbon atoms and the two R.sub.4 groups can be the
same or different,
a group having the formula R.sub.3 N (R.sub.5).sub.3 A where R.sub.3 is a
bivalent hydrocarbon radical having from 1 to 4 carbon atoms, wherein any
carbon to carbon bond is either a single or a double bond, and not more
than one is a double bond; A is a physiologically acceptable anion and
R.sub.5 is an alkyl group having from 1 to 2 carbon atoms and the three
R.sub.5 groups can be the same or different,
a group having the formula R.sub.3 OH where R.sub.3 is a bivalent aliphatic
hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to
carbon bond is either a single or a double bond, and not more than one is
a double bond, or
CO.sub.2 R', CH.sub.2 CO.sub.2 R' or CH.sub.2 CH.sub.2 CO .sub.2 R' where
R' is H, or an alkyl group other than t-butyl having from one to four
carbon atoms, with the provisos that R11 can be SO.sub.3 H or a salt
thereof, that, in the foregoing chlorinimines and metal complexes, either
R3 or R4 can be a CH.sub.2 group or O which, in either case, is bonded to
the carbon of the pyrrole ring by a double bond, that, in the foregoing
families of compounds which are designated Isobacteriochlorinimines I and
Isobacteriochlorinimines II and their metal complexes, either R1 or R2 can
be a CH2 group or O which, in either case, is bonded to the carbon of the
pyrrole group ring by a double bond and, when either R1 or R2 is a
Ch.sub.2 or O, either R3 or R4 is also a CH.sub.2 group or O which is
bonded to the carbon of the pyrrole ring by and double bond, and that in
the foregoing families of compounds which are designated
bacteriochlorinimines and metal complexes, either R3 or R4 can be a
CH.sub.2 group or O which, in either case, is bonded to the carbon of the
pyrrole ring by a double bond and, when either R3 or R4 is a CH.sub.2
group or O, either R7 or 8 is also a CH.sub.2 group or O which is bonded
to the carbon of the pyrrole ring by and double bond.
Description
FIELD OF THE INVENTION
This invention relates to the production and use of imines of porphyrins,
of porphyrins, and of related compounds, including metal complexes, e.g.,
benzochlorinimines and benzochlorinimine metal complexes, which are useful
in photodynamic therapy. The invention also relates to compositions
containing such imines. Specific examples of the benzochlorinimines and of
the benzochlorinimine metal complexes of the invention have the following
structures:
##STR2##
where M comprises a metal cation that is complexed with two of the
nitrogens of the benzochlorin and is Ag, Al, Ce, Co, Cr, Cu, Dy, Er, Eu,
Fe, Ga, Gd, Hf, Ho, In, La, Lu, Mn, Mo, Nd, Ni, Pb, Pd, Pr, Pt, Rh, Sb,
Sc, Sm, Sn, Tb, .sup.99m Tc, Th, Ti, Tl, Tm, U, V, Y, Yb, Zn or Zr, and A
is a physiologically acceptable anion, e.g., chloride.
The benzochlorins, benzochlorin metal complexes, and the other imines and
imine metal complexes according to the instant invention are photo
sensitizers; i.e., excitation at a suitable wavelength promotes them to
the singlet state, from which they decay to the ground state primarily by
non-radiative pathways, releasing their energy in several forms, including
heat, electron transfer, and probably forming at least one active oxygen
species, free radicals, or both. Further, when they are suitably
administered, for example, intravenously, to a living patient, they are
rejected by healthy tissue, but not by tumors and, as a consequence, they
are still present, a suitable time after administration, in tumors of the
patient to whom they were administered, but are no longer present in
adjacent healthy tissue so that they can be promoted to the singlet state
by excitement at a suitable wavelength and will then destroy the tumor as
they decay to the ground state. Photothermal sensitizers, which destroy
tumors by the release of heat after they have been promoted to the singlet
state, are discussed by Jori, G. et al., Journal of Photochemistry and
Photobiology, B: Biology, 6 (1990), pages 93-101. Sensitizers that, after
they have been promoted to the singlet state, produce active oxygen
species, probably including singlet oxygen, which then destroys tumors are
also known, being disclosed, for example, in "Morgan et al. I", U.S. Pat.
No. 4,988,808, Jan. 29, 1991 and in references cited therein.
DISCUSSION OF RELATED ART
Benzochlorin metal complexes and benzochlorins having the formulas of FIGS.
1 and 2, below, are disclosed in Morgan et al. I:
##STR3##
Compounds having the structures of FIGS. 1 and 2 are also disclosed by
Morgan et al., "Photodynamic Action of Benzochlorins", SPIE Vol.
1066-Photodynamic Therapy: Mechanisms (1989), pages 146 et seq. and by
Vicente et al. "Vilsmeier Reactions of Porphyrins and Chlorins with
3-(Dimethylamimo)acrolein To Give meso-(2-Formylvinyl)porphyrins: * * * "
J. Org. Chem. 1991, 56, pages 4407-4418 (see, also, Arnold, D. P. et al.,
Journal of The Chemical Society, Perkin Transactions I (1979), pages 1660
et seq.). The specific benzochlorins disclosed by Morgan et al. are
compounds where each of R1 through R8 is ethyl, each of R10 through R12 is
hydrogen, and
(a) the compound has the structure of FIG. 1, R14 is SO.sub.3 Na and M is
Sn;
(b) the compound has the structure of FIG. 2 and R14 is H;
(c) the compound has the structure of FIG. 2 and R14 is SO.sub.3 Na; and
(d) the compound has the structure of FIG. 1, R14 is H, and M is Sn.
Similarly, porphyrins, chlorins, bacteriochlorins, chlorophylls,
bacteriochlorophylls, purpurins, reduced purpurins, verdins, Diels-Alder
Adducts, isobacteriochlorins, and metal complexes of the foregoing are all
known, as is the use of the Vilsmeier reagent to introduce formyl groups
into porphyrins; the reaction of the Vilsmeier reagent (dimethylformamide,
for example, and phosphoryl chloride) produces imines as intermediates. So
far as is known, however, the imines produced by the Vilsmeier reagent
have not previously been separated from the reaction mixture; instead, the
reaction has been allowed to proceed until the formyl group was formed.
BRIEF DESCRIPTION OF THE PRESENT INVENTION
The present invention is a family of imines, e.g., benzochlorinimines
having the structure set forth below and identified by legend, and a
family of imine metal complexes, e.g., benzochlorinimine metal complexes
having the structure set forth below and identified by legend, and a
method for treating tumors which involves the administration of one of the
imines, e.g., a benzochlorinimine having the structure set forth below, or
one of the imine metal complexes, e.g., a benzochlorinimine metal complex
having the structure set forth below, to a human or animal patient with a
tumor, and, after a suitable period of time, irradiation of the tumor with
light of a suitable wavelength and of sufficient intensity to promote the
imine or imine metal complex to the singlet state.
##STR4##
In the benzochlorinimines and benzochlorinimine metal complexes having the
foregoing formulas:
M and A have the meanings indicated above, R' and R" can be the same or
different and each is hydrogen, an alkyl group having from 1 to 4 carbon
atoms, or the two, together, can consist of two CH.sub.2 groups each of
which is bonded to the nitrogen atom, and the two of which are a part of
an aliphatic hydrocarbon chain having from 4 to 6 carbon atoms, and each
of R1 through R8 and R11 is
H or CHO,
an alkyl group other than t-butyl having from 1 to 4 carbon atoms,
an alkylene group having from 2 to 4 carbon atoms,
a group having the formula R.sub.3 N(R.sub.4).sub.2 where R.sub.3 is a
bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms,
wherein any carbon to carbon bond is either a single or a double bond, and
not more than one is a double bond; R.sub.4 is hydrogen or an alkyl
radical having from 1 to 2 carbon atoms and the two R.sub.4 groups can be
the same or different,
a group having the formula R.sub.3 N(R.sub.5).sub.3 A where R.sub.3 is a
bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms,
wherein any carbon to carbon bond is either a single or a double bond, and
not more than one is a double bond; A is a physiologically acceptable
anion and R.sub.5 is an alkyl group having from 1 to 2 carbon atoms and
the three R.sub.5 groups can be the same or different,
a group having the formula R.sub.3 OH where R.sub.3 is a bivalent aliphatic
hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to
carbon bond is either a single or a double bond, and not more than one is
a double bond, or
CO.sub.2 R', CH.sub.2 CO.sub.2 R' or CH.sub.2 CH.sub.2 CO.sub.2 R', where
R' is H, or an alkyl group other than t-butyl having from one to four
carbon atoms,
with the proviso that R11 can be SO.sub.3 H or a salt thereof.
Other imines and imine metal complexes of the families of the instant
invention have the formulas set forth below, and identified by legend.
##STR5##
In the foregoing formulas, M comprises a metal cation that is complexed
with two of the nitrogens of the benzochlorin and is Ag, Al, Ce, Co, Cr,
Cu, Dy, Er, Eu, Fe, Ga, Gd, Hf, Ho, In, La, Lu, Mn, Mo, Nd, Ni, Pb, Pd,
Pr, Pt, Rh, Sb, Sc, Sm, Sn, Tb, .sup.99nr Tc, Th, Ti, Tl, Tm, U, V, Y, Yb,
Zn or Zr,
A is a physiologically acceptable anion, e.g., chloride, R' and R" can be
the same or different and each is hydrogen, an alkyl group having from 1
to 4 carbon atoms, or the two, together, can consist of two CH.sub.2
groups each of which is bonded to the nitrogen atom, and the two of which
are a part of an aliphatic hydrocarbon chain having from 4 to 6 carbon
atoms, and each of R1 through R11 is
H or CHO,
an alkyl group other than 1-butyl having from 1 to 4 carbon atoms,
an alkylene group having from 2 to 4 carbon atoms,
a group having the formula R.sub.3 N(R.sub.4).sub.2 where R.sub.3 is a
bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms,
wherein any carbon to carbon bond is either a single or a double bond, and
not more than one is a double bond; R.sub.4 is hydrogen or an alkyl
radical having from 1 to 2 carbon atoms and the two R.sub.4 groups can be
the same or different,
a group having the formula R.sub.3 N(R.sub.5).sub.3 A where R.sub.3 is a
bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms,
wherein any carbon to carbon bond is either a single or a double bond, and
not more than one is a double bond; A is a physiologically acceptable
anion and R.sub.5 is an alkyl group having from 1 to 2 carbon atoms and
the three R.sub.5 groups can be the same or different,
a group having the formula R.sub.3 OH where R.sub.3 is a bivalent aliphatic
hydrocarbon radical having from 1 to 4 carbon atoms, wherein any carbon to
carbon bond is either a single or a double bond, and not more than one is
a double bond, or
CO.sub.2 R', CH.sub.2 CO.sub.2 R' or CH.sub.2 CH.sub.2 CO.sub.2 R' where R'
is H, or an alkyl group other than t-butyl having from one to four carbon
atoms,
with the proviso that R11 can be SO.sub.3 H or a salt thereof.
In the foregoing Chlorinimines and metal complexes, either R3 or R4 can be
a CH.sub.2 group or O which, in either case, is bonded to the carbon of
the pyrrole ring by a double bond. Likewise, in the foregoing families of
compounds which are designated Isobacteriochlorinimine I and
Isobacteriochlorinimine II either R1 or R2 can be a CH.sub.2 group or O
which, in either case, is bonded to the carbon of the pyrrole ring by a
double bond and, when either R1 or R2 is a CH.sub.2 group or O, either R3
or R4 is also a CH.sub.2 group or O which is bonded to the carbon of the
pyrrole ring by a double bond. Finally, in the foregoing families of
compounds which are designated bacteriochlorinimine either R3 or R4 can be
a CH.sub.2 group or O which, in either case, is bonded to the carbon of
the pyrrole ring by a double bond and, when either R3 or R4 is a CH.sub.2
group or O, either R7 or R8 is also a CH.sub.2 group or O which is bonded
to the carbon of the pyrrole ring by a double bond.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The following examples constitute the best modes presently contemplated by
the inventors, but are presented solely to illustrate and disclose the
invention, and are not intended to be limiting.
As used herein, and in the appended claims, the terms "percent" and "parts"
refer to percent and parts by weight, unless otherwise indicated; g means
gram or grams; mg means milligram or milligrams; ng means nanogram or
nanograms; pg means picogram or picograms; cm means centimeter or
centimeters; mm means millimeter or millimeters; L means liter or liters;
mL means milliliter or milliliters; .mu.L means microliter or microliters;
.sup.v /.sub.v means percent by volume; .sup.m /.sub.o means mole percent,
and equals 100 times the number of moles of the constituent designated in
a composition divided by the total number of moles in the composition;
.sup.v /.sub.v means percent by volume; .sup.w /.sub.v means weight per
unit of volume, and is in terms of g/L; M means molar and equals the
number of gram moles of a solute in one liter of a solution; .mu.M means
micromolar and equals the number of microgram moles in one liter of a
solution; mM means millimolar and equals the number of milligram moles of
a solute in one liter of a solution; N means normal, and equals the number
of gram equivalents of a solute in one liter of solution; .mu.N means
micronormal and equals the number of microgram equivalents of a solute in
one liter of solution; and mW means milliwatt or milliwatts. All
temperatures are in .degree.C., unless otherwise indicated.
Example 1 describes the production of "Cu Benzochlorinimine I" (Formula II,
supra, where M is Cu and A is Cl.sup.-). In Example 1 , Cu
Benzochlorinimine I is produced from a solution of 30 dichloroethane of 1
mL Vilsmeier reagent and 80 mg "Cu Octaethyl Benzochlorin" (Vicente et
al., supra):
##STR6##
EXAMPLE 1
The Vilsmeier reagent was produced by mixing 0.5 mL phosphoryl chloride
with 0.5 mL dimethyl formamide, and was then added to a solution of the Cu
Octaethyl Benzochlorin in the dichloroethane, which solution had been
heated to a temperature in the range of 60.degree. to 65.degree.. The
reaction mixture was stirred for 15 minutes at a temperature within the
temperature indicated range, and was then washed with deionized water.
After removal of the solvent under reduced pressure, the crude product
which remained was purified by recrystallization from
dichloromethane/hexane. The yield was 80 mg Cu Benzochlorinimine I (87
percent of theory). The Cu Benzochlorinimine I was identified by high
resolution mass spectrometry; in dichloromethane solvent it has absorbance
peaks in the visible spectrum at wavelengths of 386, 448, 570, 690 and 752
nm (51000, 30000, 7000, 12000, 35000).
The procedure of Example 1 has been repeated, except that equivalent
amounts of other formamides were substituted for the dimethylformamide to
produce other copper octaethyl benzochlorinimines. The formamides used had
the formulas given in the following table, and produced benzochlorinimine
metal complexes which had the structure previously identified by legend
where R1 through R8 were ethyl, R11 was hydrogen, A.sup.- was chloride, M
was copper, and the imine group had the structure given in the table:
__________________________________________________________________________
Number assigned to Formula for imine group of
Cu Benzochlorinimine
Formula of formamide used
benzochlorinimime metal complex
__________________________________________________________________________
II
##STR7##
##STR8##
III
##STR9##
##STR10##
IV
##STR11##
##STR12##
##STR13##
##STR14##
__________________________________________________________________________
In vitro and in vivo testing of Cu Benzochlorinimine I was also carried out
by established procedures. The cells used for the in vitro testing were
AY-27FANFT transitional cell bladder cancer cells attached to 28 cm.sup.2
culture dishes. Cu Benzochlorinimine I was added to the culture dishes at
four concentrations: 0.1, 0.25, 0.5 and 1 .mu.g per mL, and "Cremophor E"
(defined below) was added as a control at 1 .mu.g per mL. Four hours after
the Cu Benzochlorin I and "Cremophor E" additions, the cells were washed,
irradiated, in one series of tests with a pulsed beam (750 nm) from an
Alexandrite laser and, in another series of tests, with a continuous beam
(590 nm) from a xenon are lamp. The irradiated cells were then incubated
for 4 to 7 days until colony formation occurred. Surviving colonies were
then counted, and mean values for surviving colonies were determined. The
results, when the Alexandrite laser was used, in terms of the mean numbers
of surviving colonies as a function of the fluence of radiation in Joules
per cm.sup.2, are summarized in the following table.
______________________________________
Imine Concentration
Fluence surviving colonies, mean
______________________________________
1.0 0 550
0.5 0 772
0.25 0 850
0.1 0 898
Control 0 919
1.0 1.05 110
0.5 1.05 597
0.25 1.05 843
0.1 1.05 816
Control 1.05 832
1.0 2.1 18
0.5 2.1 207
0.25 2.1 756
0.1 2.1 701
Control 2.1 823
0.5 6.3 7
0.25 6.3 51
0.1 6.3 485
Control 6.3 846
0.25 10.5 2
0.1 10.5 83
Control 10.5 850
______________________________________
To conduct the foregoing tests, the Cu Benzochlorinimine I was dissolved in
a commercially available non-ionic solubilizer and emulsifier obtained by
reacting ethylene oxide with castor oil in a ratio of 35 moles of ethylene
oxide per mole of castor oil, diluting the resulting solution with
1,2-propanediol, and producing an emulsion with the resulting solution and
0.9 percent aqueous sodium chloride solution. The specific non-ionic
solubilizer used is available from BASF under the designation CREMOPHOR
EL; it is composed of fatty acid esters of polyglycols, glycerol
polyglycols, polyethylene glycols and ethoxylated glycerol. The test
solutions were prepared from 50 mg Cu Benzochlorinimine I, about 1 mL warm
solubilizer (enough to dissolve the test compound), and enough
1,2-propanediol to make a solution of the Cu Benzochlorinimine I in a
mixed diol/solubilizer solvent containing 32.9 percent solubilizer;
finally, enough 0.9 percent aqueous sodium chloride was added to make 10
mL test solution so that the final concentration of the Cu
Benzochlorinimine I in the test solution was 5 mg per mL. Each test
solution was made, with mechanical shaking and stirring, by dissolving the
Cu Benzochlorinimine I in the solubilizer, diluting the resulting solution
with the indicated amount of 1,2-propanediol, and adding the sodium
chloride solution to the diluted solution. A control solution was also
prepared for use with each test solution. The control was identical with
the test solution except that it contained no Cu Benzochlorinimine I.
The results of the in vitro testing, when the Xenon arc lamp was used, in
terms of the mean numbers of surviving colonies as a function of the
fluence of radiation in Joules per cm.sup.2, are summarized in the
following table.
______________________________________
Imine Concentration
Fluence surviving colonies, mean
______________________________________
1.0 0 115
0.5 0 841
0.25 0 942
0.1 0 905
Control 0 928
0.5 1.05 193
0.25 1.05 689
0.1 1.05 731
Control 1.05 836
0.5 2.1 28
0.25 1.1 317
0.1 2.1 703
Control 2.1 795
0.25 6.3 5
0.1 6.3 51
Control 6.3 907
0.1 10.5 2
Control 10.5 841
______________________________________
The in vivo testing was conducted on male Fisher 344 rats weighing 135 to
150 g in whom the transplantable FANFT
(N- 4-(5-nitro-2-furyl)-2-thiazolyl!formamide tumor system had been
implanted. (Use of this system is reported by Selman, S. H., et al.,
Cancer Research, pp. 1924-1927, May, 1984.) Two tumors were implanted into
the subcutaneous tissue of the flank of each test animal; when the testing
was carried out, each tumor was about 1 cm in diameter.
The Cu Benzochlorinimine I was dissolved in the previously identified
non-ionic solubilizer that is commercially available under the designation
CREMOPHOR EL, and test solutions which contained 2 mg per mL Cu
Benzochlorinimine I were prepared as previously described.
The testing involved injecting each rat with a solution of the Cu
Benzochlorinimine I, dosage 3.5 mg per kg of body weight or 7 mg per kg of
body weight or with the same volume of the appropriate control,
irradiating one of the two tumors with laser light, in some cases,
observing the animals over a period of time and, in others, sacrificing
the animals, and examining the tumors. The injections were made via the
dorsal tail vein. The irradiation of one of the tumors occurred twenty
four hours after each rat was injected while the other of the two tumors
was shielded.
Tumor temperature and body core temperature were monitored, using
thermistors, one placed percutaneously beneath the tumor and one placed
intrarectally. Tumor temperature was kept within 2.degree. of body core
temperature by directing a jet of cool air over the tumor.
Both the Alexandrite laser and the Xenon arc lamp were used to irradiate
the tumors. The light intensity on the tumor was monitored; each tumor
received 200 mW per cm.sup.2 (360 Joules per cm.sup.2).
Twenty four hours after the irradiation, some of the rats that had been
injected with the test solution and one of the rats that had been injected
with the control were sacrificed by an intracardiac injection of saturated
aqueous potassium chloride solution. Others of the rats that had been
injected with the test solution and with the control solution were
observed over a period of time. During the testing, the rats were under
barbituate anesthesia (65 mg per kg body weight).
The tumors from the sacrificed rats were excised, placed in 10 percent
phosphate-buffered formalin and cut into three sections perpendicular to
their long axis. The tumors were then embedded in paraffin and cut into
sections five microns in width. The sections were stained with hematoxylin
and eosin.
Histologic examination of the stained sections (twenty four hours after a
tumor was irradiated by either light source) revealed extensive necrosis
of cancer cells in tumors of rats that had been injected with Cu
Benzochlorinimine, and no necrosis of tumor cells in rats that had been
injected with Cremophor. The examination revealed no necrosis of cells of
tumors that were not irradiated. Fourteen days after irradiation, the
irradiated tumors of three of the six rats that were not sacrificed and
had been injected with 7 mg Cu Benzochlorinimine per kg of body weight
showed no sign of tumor regrowth.
SKH1 hairless mice (five animals) were injected with Cu Benzochlorinimine
(7 mg per kg of body weight), and the five animals were subjected to light
treatment one day after the injection. One of the animals showed slight
skin burn, while the other animals showed no skin damage. This indication
is important, because extensive and prolonged skin damage is a common side
effect of other sensitizers.
The production of Cu Benzochlorinimine I by reaction between Cu Octaethyl
Benzochlorin and a Vilsmeier reagent produced from phosphoryl chloride and
dimethyl formamide is described in Example 1. The structure of Cu
Octaethyl Benzochlorin is given above; its structure is also that of FIG.
1, above, where R1 through R8 are ethyl, R10 through R12 and R14 are
hydrogen, and M is Cu; the reaction introduced a substituent having the
formula --CH.dbd.N.sup.+ (CH.sub.3).sub.2. This was an R10 substituent in
the FIG. 1 formula for Cu Octaethyl Benzochlorin. As has been stated
above, other R10 substituents have been introduced, using the Example 1
procedure to react Cu Octaethyl Benzochlorin with Vilsmeier reagents from
phosphoryl chloride and formamides other than dimethyl formamide, e.g.,
diethyl formamide, diisopropyl formamide, di n-butyl formamide, cyclic
formamides, and the like. In general, by using different formamides,
benzochlorins can be produced which have the Formula II structure except
that one of the CH.sub.3 groups of the R10 substituent is replaced by an
alkyl group having from 2 to 4 carbon atoms or where both of the CH.sub.3
groups are so replaced; the two alkyl groups can be the same or different.
Imines where R' is hydrogen, R" is hydrogen, or both R' and R" are
hydrogen can also be prepared by conducting the reaction between Cu
Octaethyl Benzochlorin or the like and the Vilsmeier reagent to introduce
a formyl group into the molecule (see the second paragraph of Example A,
infra) and then reacting the formyl group with ammonia, a primary alkyl
amine, or a secondary alkyl amine, to produce, respectively, an imine
where R' and R" are both hydrogen, an imine where one of R' and R" is
hydrogen and the other is an alkyl group, and an imine where both R' and
R" are alkyl groups. In any case, the alkyl group has from one to four
carbons. As disclosed above, imines including cyclic structures can also
be produced, e.g., where R' and R" are both CH.sub.2, each of which is
bonded to the nitrogen atom, and the two of which are a part of an
aliphatic hydrocarbon chain having from 4 to 6 carbon atoms.
Similarly, the procedure of Example 1 can be used to introduce
--CH.dbd.N.sup.+ (CH.sub.3).sub.2 and other imine substituents into copper
complexes of benzochlorins other than Cu Benzochlorin I, and, generally,
into benzochlorin metal complexes having the structure of FIG. 1, supra
where R1 through R8 and M have the meanings set forth above, R10 through
R12 are hydrogen, and R14 can have the same meaning as R1 through R8, and
can also be SO.sub.3 H or a salt thereof. For example, the Cu or the Ni
complex of octaethylbenzochlorin, compounds which have the structure of
FIG. 1, supra, where R1 through R8 are ethyl, R10, R11, R12 and R14 are
hydrogen, and M is copper or nickel, can be produced from
octaethylporphyrin by the procedure of Example A, below, and can be
reacted by the procedure of Example 1 to produce a benzochlorinimine
according to the invention having the structure set forth above where R1
through R8 are ethyl, R11 is hydrogen, A is Cl.sup.-, and M is Cu or Ni.
The identities of R' and R" depend upon the identity of the formamide
used. Six intermediates were produced in the procedure of Example A, I!
nickel octaethylporphyrin II!, nickel meso-formyloctaethylporphyrin,
III! Nickel meso-(.beta.-ethoxy-carbonylvinyl)-octaethylporphyrin IV!,
meso-(.beta.-ethoxy carbonylvinyl)-octaethylporphyrin, and
V!meso-(.beta.-hydroxyvinyl)-octaethylporphyrin, and VI!
octaethylbenzochlorin, in addition to VII! Nickel or Copper
octaethylbenzochlorin, from the octaethylporphyrin, which has the
structure of FIG. 3, below, where, R1 through R8 are ethyl, and R is
hydrogen. FIG. 3 is a general formula for porphyrins. The nickel
octaethylporphyrin, the nickel meso-formyloctaethylporphyrin, the Nickel
meso-(.beta.-ethoxy-carbonylvinyl)-octaethylporphyrin, and the
meso-(.beta.-hydroxymethylvinyl)- octaethylporphyrin, all had the
structure of FIG. 4, below, where R1 through R8 were ethyl. In the nickel
octaethylporphyrin R was H; in the meso-formyloctaethylporphyrin R was
CHO; in the nickel meso-(.beta.-ethoxy-carbonylvinyl)-octaethylporphrin R
was CH.dbd.CHCO.sub.2 CH.sub.2 CH.sub.3 ; in the
meso-(.beta.-hydroxy-methylvinyl)-octaethylporphyrin R was
CH.dbd.CHCH.sub.2 OH. FIG. 4 is a general structure for nickel complexes
of porphyrins.
##STR15##
The nickel octaethylporphyrin is first produced from 100 mg nickel acetate
and a solution of 20 mg octaethylporphyrin in a mixed solvent composed of
15 mL dichloromethane and 5 mL methanol.
Example A
Production of Nickel octaethylporphyrin
The nickel acetate is added to the octaethylporphyrin solution; the mixture
which results is refluxed for about 24 hours until the electronic spectrum
of the reaction mixture indicates that chelation is complete. The reaction
mixture is then concentrated to 7 mL and allowed to cool to room
temperature of about 22.degree.. Product which precipitates is recovered
by filtration, dissolved in a mixed solvent composed of 5 mL
dichloromethane and 2 mL methanol, and recrystallized, yielding Ni
octaethylporphyrin.
Production of nickel meso-formyloctaethylporphyrin
Nickel meso-formyloctaethylporphyrin is produced (Grigg, R. et al., J.
Chem. Soc. Perkin Trans I, 1972, pages 1789-1799) from a solution of 200
mg nickel meso-octaethylporphyrin in 150 mL 1,2-dichloroethane and 4.8 mL
of a solution of phosphoryl chloride in dimethylformamide prepared by
making a dropwise addition of 13.7 mL freshly distilled phosphoryl
chloride to 10 mL dry dimethylformamide that has been cooled on an ice
bath, and keeping the solution at room temperature of about 22.degree. for
30 minutes. The 4.8 mL portion of the phosphoryl chloride solution is
warmed to 50.degree. on a water bath and the nickel
meso-octaethylporphyrin solution is added dropwise thereto; the resulting
reaction mixture is maintained at a temperature of 50.degree.-55.degree.
and stirred for 15 minutes and is then warmed for an additional 30
minutes. A 150 mL portion of a saturated aqueous solution of sodium
acetate is then added to the reaction mixture, after which stirring and
heating are continued for an additional two hours. The organic and the
aqueous layers are separated; the aqueous layer is extracted twice with
100 mL portions of diethyl ether; and the ether extracts are added to the
organic layer. The organic solvents are then removed under reduced
pressure, and the residue is dissolved in chloroform and chromatographed
on an alumina column (3.times.30 cm). The product is crystallized from a
mixed chloroformethanol solvent as long red felted needles.
The nickel meso-(.beta.-ethoxycarbonylvinyl) octaethylporphyrin was
produced from a solution in 50 mL Xylene of 506 mg nickel
meso-formyloctaethylporphyrin and 1.024 g (carbethoxymethylene)-triphenyl
phosphorane.
Production of nickel meso-(.beta.-ethoxycarbonylvinyl) octaethylporphyrin
The xylene solution of nickel meso-formyloctaethylporphyrin and
(carbethoxymethylene)-triphenyl phosphorane was heated under reflux for 18
hours. The solution was cooled; the xylene was removed in vacuo; and the
solid which remained was dissolved in the minimum amount of
dichloromethane and chromatographed on silica. A minor fraction of nickel
meso-formyloctaethylporphyrin and a major red fraction were recovered. The
solvent was removed from the red fraction; the solid which remained was
recrystallized from a solvent composed of equal parts by volume of
dichloromethane and methanol, yielding 455 mg small brown needles. The
product was identified by nuclear magnetic resonance as nickel
meso-(.beta.ethoxycarbonylvinyl) octaethylporphyrin.
Production of meso- .beta.-(ethoxycarbonyl)vinyl! octaethylporphyrin
A solution of 621 mg of nickel meso-(.beta.-ethoxycarbonylvinyl)
octaethylporphyrin in 10 mL concentrated sulfuric acid is allowed to stand
at room temperature of about 22.degree. for 2 hours. Additions of 100 mL
dichloromethane and enough saturated sodium bicarbonate to neutralize the
reaction mixture are then made. The organic layer is then collected,
washed and dried, and the solvent is removed. The crude product is
purified by crystallization from dichloromethant-methanol.
Production of meso- 3-(hydroxy)propenyl! octaethylporphyrin
A solution of 200 mg meso- .beta.-(ethoxycarbonyl)vinyl! octaethylporphyrin
in 100 mL dry tetrahydrofuran is cooled under nitrogen to -78.degree.,
using an acetone/dry ice bath. An excess of diisobutyl aluminum hydride in
dry tetrahydrofuran (20 mL of 1M solution) is then added, followed by one
hour of stirring at reduced temperature. Additions are then made of 100 mL
water, 100 mL of a 10 percent aqueous solution of sodium hydroxide, and
200 mL water, and the resulting mixture is stirred for 30 minutes at room
temperature of about 22.degree.. The organic layer is then collected,
washed and dried, and the solvent is removed under vacuum. The crude
product is purified by crystallization from dichloromethane-methanol.
Production of octacthylbenzochlorin
A solution of 150 mg meso- 3-(hydroxy)propenyl! octacthylporphyrin in 3 mL
concentrated sulfuric acid is kept at room temperature for 5 minutes,
after which time a 20 mL portion of dichloromethane is added to the
solution. Saturated aqueous sodium bicarbonate is then added until the
reaction mixture is neutral. The organic layer is then collected, washed
and dried, and the solvent is removed. The crude product was purified by
crystallization from dichloromethane-methanol which contained 9.sup.v
/.sub.v methanol.
Production of Ni octaethylbenzochlorin
A solution is prepared by dissolving 20 mg octaethyl benzochlorin in a
mixed solvent composed of 15 mL dichloromethane and 5 mL methanol and a
100 mg portion of nickel acetate is added to the solution; the mixture
which results is refluxed for about 2 hours until the electronic spectrum
of the reaction mixture indicates that chelation is complete. The reaction
mixture is then concentrated to 7 mL and allowed to cool to room
temperature of about 22.degree.. Product which precipitates is recovered
by filtration, dissolved in a mixed solvent composed of 5 mL
dichloromethane and 2 mL methanol, and recrystallized, yielding the Ni
complex of octaethylbenzochlorin.
Production of Cu octaethylbenzochlorin
A solution was prepared by dissolving 20 mg octaethyl benzochlorin (Morgan
et al., "Observations on the Synthesis and in vivo Photodynamic Activity
of some Benzochlorins", Photochemistry and Photobiology Vol. 55, No. 1,
pages 133-136, 1992) in a mixed solvent composed of 15 mL dichloromethane
and 5 mL methanol and a 100 mg portion of copper acetate was added to the
solution; the mixture which resulted was refluxed for about 2 hours until
the electronic spectrum of the reaction mixture indicated that chelation
was complete. The reaction mixture was then concentrated to 7 mL and
allowed to cool to room temperature of about 22.degree.. Product which
precipitated was recovered by filtration, dissolved in a mixed solvent
composed of 5 mL dichloromethane and 2 mL methanol, and recrystallized,
yielding the Cu complex of octaethylbenzochlorin (yield, 90 percent of
theory).
The procedure of Example 1 can be used to produce benzochlorinimine
according to the invention from Ni octaethylbenzochlorin and from other
benzochlorins which can be produced by the method of Example A from the
corresponding porphyrins (note that the identities of R1 through R8 in the
Ni benzochlorins of the invention are the same as in the porphyrin
starting material for Example A; this is generally true). Porphyrins
having an appropriate structure to produce benzochlorinimine metal
complexes according to the instant invention (formula setforth above, and
identified by legend where R11 is hydrogen) are either known or can be
produced by known reactions from the requisite dipyrrolic intermediates,
e.g., dipyrromethanes and dipyrromethenes, which, in turn are either known
or can be synthesized from the requisite pyrroles. The requisite pyrroles,
if not available, can be synthesized from the requisite pyrroles. The
requisite pyrroles, if not available, can be synthesized by the classical
Knorr Reaction and variations, and by other known reactions, and can be
manipulated and transformed (see, for for example, David Dolphin, The
Porphyrins, Volume I, Structure and Synthesis, Part A, Academic Press, New
York, San Francisco and London, 1978, pages 101-163). The pyrroles have
the following structure:
##STR16##
where A can be H, CH.sub.3, an ester, a nitrile, a cyanovinyl or an amide
group, D can be H, an ester, a nitrile, a cyanovinyl or an amide group and
B and C are substituents which appear in the ultimate porphyrin,
frequently lower alkyl groups, particularly methyl and ethyl.
Dipyrrolic intermediates, e.g., dipyrromethanes and dipyrromethenes, can be
synthesized from pyrroles, and can be converted to porphyrins by known
reactions; some porphyrins can be synthesized directly from pyrroles (see,
for example, David Dolphin, supra, pages 85-100 and 163-234).
Dipyrromethanes and dipyrromethenes have the following structures.
##STR17##
By way of example, "Octamethylpor phyrin" can be synthesized by heating
3,4-dimethylpyrrole (foregoing structure, where A is HOOC, B and C are
CH.sub.3 and D is CH.sub.2 OH) at 160.degree.-170.degree. and
"Octaethylporphyrin" can be synthesized by heating 3,4-diethylpyrrole,
where A is HOOC, B and C are CH.sub.2 CH.sub.3 and D is CH.sub.2 OH.
Porphyrins can also be produced from dipyrromethanes by way of an aldehyde
coupling reaction, a formic acid or orthoformate ester condensation, by
the "dialdehyde synthesis" or by the Vilsmeier pyrroketone synthesis, and
from dipyrromethenes by the Fischer synthesis, or by reaction with
dipyrromethanes. The porphyrins that are produced have the following
structure where R is hydrogen and R1 through R4 and R5 through R8 have the
same meanings as B, C, E and F in the dipyrromethane and dipyrromethene
starting materials when the porphyrins are synthesized from these
precursors:
##STR18##
In octamethylporphyrin and octaethylporphyrin, R is hydrogen and R1 through
R8 are methyl in the former and ethyl in the latter.
Ni Octaethylporphyrin, Ni Octamethylporphyrin and Ni complexes of other
known porphyrins and of porphyrins which can be synthesized by the
procedures summarized above produce, when used in the procedure of Example
A, Ni complexes of benzochlorins having the structure of FIG. 1, supra,
where M is Ni and R10, R11, R12 and R14 are hydrogen. These benzochlorins,
when used in the procedure of Example 1, produce Cu or Ni
benzochlorinimines according to the invention having the structure set
forth above, where R11 is hydrogen. The benzochlorins of FIG. 1 can be
reacted with the Vilsmeier reagent to introduce a formyl group as R10. The
formyl group, after separation of the isomers, if necessary, can be
reduced to CH.sub.3, or can be
The method of Example C, supra, can be used to produce metal complexes of
benzochlorinimines according to the invention. Specifically, an equivalent
amount of a benzochlorinimines according to the invention. Specifically,
an equivalent amount of a according to the invention can be substituted
for the octaethyl benzochlorinimine, or copper acetate can be substituted
for the nickel acetate, or both substitutions can be made. In this manner,
benzochlorinimine metal complexes having the structure indicated by the
foregoing formula where M is either Cu or Ni can be produced from
benzochlorinimines having the structure indicated by the foregoing
formula. Iron complexes can be produced by the method of Example C by
substituting FeCl.sub.3 for the nickel acetate, in which case M in the
formula is Fe(Cl). NiCl.sub.2 can also be substituted, in which case M in
the formula is Ni(OH).sub.2. Other benzochlorinimine metal complexes can
also be made from the corresponding benzochlorinimines by the methods
disclosed in "Morgan et al. II", U.S. Pat. No. 4,877,872, Oct. 31, 1989
(see column 32, line 56 to column 34, line 7) for the preparation of
purpurin and chlorin metal complexes; all that is necessary is to
substitute an equivalent amount of the benzochlorinimine metal complex for
the purpurin or chlorin.
Similarly, porphyrinimine nickel complexes, chlorinimine nickel complexes,
bacteriochlorinime nickel complexess, chlorophyllimine nickel complexes,
bacteriochlorophyllimine nickel complexes, purpurinimine nickel complexes,
reduced purpurinimine nickel complexes, verdinimine nickel complexes, and
Diels Alder Adduct Imine nickel complexes, and isobacteriochlorin metal
complexes can be produced by the method of Example 1, by substituting for
the Ni Octaethyl Benzochlorin starting material an equivalent amount of
the nickel complex of an appropriate porphyrin, chlorin, bacteriochlorin,
chlorophyll, bacteriochlorophyll, purpurin, reduced purpurin, verdin,
Diels Alder adduct, or isobacteriochlorine to produce the desired imine.
The imines can then be produced from the imine metal complexes by the
method of Example B, and other imine metal complexes can then be produced
by the method of Example C and the variations discussed above. The
required porphyrin starting materials are all either available or can be
produced by the methods discussed above. The required purpurin metal
complex and reduced purpurin metal complex starting materials can all be
produced by the methods disclosed in "Morgan et al. III" (U.S. Pat. No.
5,051,415, granted, where the reduced purpurins are named as "chlorins").
The required Diels Alder Adducts can all be produced by the method of
"Levy et al." (U.S. Pat. No. 4,883,790, granted Nov. 28, 1989). The
required verdin metal complex starting materials can all be produced by
the method of Morgan et al. (supra). The required chlorin,
bacteriochlorin, chlorophyll, isobacteriochlorin, or bacteriochlorophyll
starting material can be produced by the methods disclosed in David
Dolphin, The Porphyrins, Volume II, Academic Press, New York, San
Francisco and London, 1978, (see pages 1-85 and 131-156). The required
bacteriochlorin Diels Alder Adducts to produce Imines I, II and III
thereof can be produced as described in Morgan et al., J. Med. Chem,
1990-1991, Volume 34, No. 7, pages 2126-2133, and the required starting
materials to produce the Chlorinimines and metal complexes, the families
of compounds which are designated Isobacteriochlorinimine I and
Isobacteriochlorinimine II and the metal complexes thereof and the
families of compounds which are designated bacteriochlorinimine and the
metal complexes thereof, which include a CH.sub.2 group or O which, in
either case, is bonded to a carbon of the pyrrole ring by a double bond,
can all be produced by procedures which are disclosed in the literature. A
dimer composed of one molecule of any of the imines or imine metal
complexes of the instant invention and a second molecule of the same or a
different imine or imine metal complex of the instant invention or the
parent porphyrin, chlorin, bacteriochlorin, chlorophyll,
bacteriochlorophyll, purpurin, reduced to CH.sub.2 OH or convened to an
oxime group, which can then be converted to a cyano group, which, in turn,
can be converted to an amide. The formyl group can also be reacted with
Wittig reagents to give alkyl, alkenyl or carboxy side chains or to
introduce the previously identified substituents which have an amine or an
alcoholic OH function in the R9 or in the R10 position.
The procedure of Example 1, supra, produces Cu Benzochlorinimine I from Cu
octaethyl benzochlorin. While octaethyl benzochlorin can be produced from
meso-(.beta.-hydroxyvinyl) -octaethyl porphyrin, it is not possible, so
far as is known, to produce the uncomplexed benzochlorinimine
corresponding with Cu Benzochlorinimine I from octaethyl benzochlorin.
Accordingly, to produce the benzochlorinimines according to the instant
invention (structures set forth above) the corresponding Ni or Cu
benzochlorinimines should be produced by the method of Example 1, and the
Ni or Cu should then be removed by acid treatment. Acid treatment to
remove metals from porphyrins is disclosed in Vicente et al., supra, and
to remove Ni from Ni Octaethyl Benzochlorin is illustrated in Example B,
below.
Example B
A 40 mg portion of Ni Octaethyl Benzochlorin was stirred for 2 1/2 hours in
4 mL concentrated (98 percent) sulfuric acid. The reaction mixture which
resulted was poured onto ice, neutralized with sodium hydrogen carbonate,
and extracted with dichloromethane. Two reaction products (20 mg of each)
were recovered by chromatographing the extract on silica gel. One of the
products was identified as Octaethyl Benzochlorin, while the other was
identified as the sulfonate thereof. The sulfonate was found to have the
structure of FIG. 2, supra, where R14 is SO.sub.3 Na, and is attached
either to the available carbon nearer R2 or to the available carbon nearer
R3, probably the former. The octaethyl benzochlorin was crystallized from
dichloromethane containing 2.sup.v /.sub.v methanol, while the octaethyl
benzochlorin sulfonate was crystallized from dichloromethane. Lambda
maximum, U V, was 657 nm for both products. The SO.sub.3 Na group can be
converted to SO.sub.3 H by acidifying the sulfonate, and the hydrogen of
the SO.sub.3 H group can be converted to other cations by neutralizing
with other bases.
The Ni and other metal complexes of the octaethyl benzochlorin and of the
octaethyl benzochlorin sulfonate can be produced from octaethyl
benzochlorin and from octaethyl benzochlorin sulfonate, a suitable
procedure for producing the Ni complex being described below as Example C.
Example C
Production of Ni octaethyl benzochlorin sulfonate
A solution is prepared by dissolving 20 mg octaethyl benzochlorin sulfonate
in a mixed solvent composed of 15 mL dichloromethane and 5 mL methanol and
a 100 mg portion of nickel acetate is added to the solution; the mixture
which results is refluxed for about 2 hours until the electronic spectrum
of the reaction mixture indicates that chelation is complete. The reaction
mixture is then concentrated to 7 mL and allowed to cool to room
temperature of about 22.degree.. Product which precipitates is recovered
by filtration, dissolved in a mixed solvent composed of 5 mL
dichloromethane and 2 mL methanol, and recrystallized, yielding the Ni
complex of octaethylbenzochlorin sulfonate, which has the structure of
FIG. 1, supra, where R1 through R8 are ethyl, R14 is SO.sub.3 H, R10, R11
and R12 are hydrogen and M is Ni. The procedure of Example 1 can then be
used to convert the Ni complex of octaethylbenzochlorin sulfonate to a
benzochlorinimine according to the invention having the structure set
forth above, and designated by legend, where R1 through R8 are ethyl, R11
is SO.sub.3 H, the identities of R' and R" depend on the dialkyl formamide
used, and A is Cl. reduced purpurin, verdin, Diels Alder adduct,
benzochlorin or a metal complex of one of the foregoing can be produced by
the method disclosed in Morgan et al. II(supra). Such dimers are products
of reaction between a CO.sub.2 R', CH.sub.2 CO.sub.2 R' or CH.sub.2
CH.sub.2 CO.sub.2 R' group of one of the imines or imine metal complexes
and an amino nitrogen or an alcoholic OH group of the other of the imines
or imine metal complexes.
By suitable substitution of starting materials, and the synthesis of
porphyrin and other starting materials as discussed above, if necessary,
the procedures of Examples A and 1 can be used to produce Ni benzochlorins
and other Ni imines according to the invention having the metal complex
structures set forth above, where M is Ni, R' and R" can be the same or
different and each is hydrogen or an alkyl group having from 1 to 4 carbon
atoms, and each of R1 through R11 is:
H or CHO,
an alkyl group other than t-butyl having from 1 to 4 carbon atoms,
an alkylene group having from 2 to 4 carbon atoms,
a group having the formula R.sub.3 N(R.sub.4).sub.2 where R.sub.3 is a
bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms,
wherein any carbon to carbon bond is either a single or a double bond, and
not more than one is a double bond; R.sub.4 is hydrogen or an alkyl
radical having from 1 to 2 carbons atoms and the two R.sub.4 groups can be
the same or different,
a group having the formula R.sub.3 N(R.sub.5).sub.3 A where R.sub.3 is a
bivalent aliphatic hydrocarbon radical having from 1 to 4 carbon atoms,
wherein any carbon to carbon bond is either a single or a double bond, and
not more than one is a double bond; A is a physiologically acceptable
anion and R.sub.5 is an alkyl group having from 1 to 2 carbon atoms and
the three R.sub.5 groups can be the same or different,
a group having the formula R.sub.3 OH where R.sub.3 is a bivalent aliphatic
radical having from 1 to 4 carbon atoms, wherein any carbon bond is either
a single or a double bond, and not more than one is a double bond, or
CO.sub.2 R', CH.sub.2 CO.sub.2 R' or CH.sub.2 CH.sub.2 CO.sub.2 R' where R'
is H, or alkyl group other than t-butyl having from one to four carbon
atoms.
Benzochlorinimines according to the invention which have the structure of
of the foregoing formula can be produced as discussed above by removing
the Cu or Ni from the corresponding Cu or Ni benzochlorinimines, and those
benzochlorinimines can be metallated as discussed above to produce
benzochlorinimine metal complexes where M comprises a metal cation that is
complexed with two of the nitrogens of the benzochlorinimine and is any of
those metals disclosed above. Similarly, other imines according to the
invention can be produced by removing Ni from the corresponding Ni imines,
and the imines can be metallized as discussed above to produce imine metal
complexes where M comprises a metal cation that is complexed with two of
the nitrogens of the imine and is any of those metals disclosed above.
An anion exchange resin can be used to introduce any desired anion (A.sup.-
in the foregoing formulas) into an imine or imine metal complex according
to the invention. The anion exchange resin is merely regenerated with a
salt or acid which has the desired anion, and the imine or imine metal
salt is poured through a column packed with the anion exchange resin.
The production of Ni Benzochlorinimine I solutions in the specific
non-ionic solubilizer that is available under the designation CREMOPHOR
EL, and the production of emulsions of such solutions with 1,2-propanediol
and saline solution is described above, as is the use of such solutions to
detect and treat Pk tumors. It will be appreciated that benzochlorinimines
and other imines according to the invention and their metal complexes can
be dissolved in other non-ionic solubilizers and that the solutions can be
used to produce emulsions that can be administrated intravenously. For
example, other reaction products of ethylene oxide and castor oil can be
so used, as can reaction products of ethylene, propylene and other similar
oxides with other fatty acids and the reaction products of propylene and
other similar oxides with castor oil. Similarly, glycols other than 1,2-
propanediol can be used in producing the emulsions for intravenous
administration, or the glycol can be omitted, particularly if the
solubilizer is prepared to have a lower viscosity and greater
compatibility with water, by comparison with the solubilizer that is
available under the designation CREMOPHOR EL. It is necessary only that
the solution or emulsion be one which is physiologically acceptable and of
a suitable concentration, or dilutable to a suitable concentration, for
intravenous administration or for local administration, should that be
desirable. An indefinitely large number of such solutions and emulsions
will be apparent to those skilled in the relevant art from the foregoing
specific disclosure. Similarly, the aqueous phase need not be 0.9 percent
or any other concentration of sodium chloride. Such saline is presently
favored for intravenous administration, but other aqueous phases can also
be used, so long as the entire composition is physiologically acceptable
for intravenous administration and, in fact, other aqueous phases may
subsequently be favored. Indeed, other aqueous phases or organic phases
may also be favored for local administration.
Dosages ranging from 3.5 to 7 mg per kg of body weight were used in the in
vivo procedures described above. It has been determined only that the
biological consequences described above were caused by the dosages
administered, not that any dosage reported is either a minimum or a
maximum. It will be appreciated, therefore, that it is necessary only to
use an effective amount of a benzochlorin or metal complex according to
the invention in the detection and treatment of tumors, preferably as
small a dosage as possible, and that the exact dosage can be determined by
routine experimentation. While systemic administration has been described
above, specifically intravenous, it will also be appreciated that local
administration will be suitable, at least in some instances.
Illumination of tumors containing a benzochlorinimine or another imine or a
metal complex is accordance with the instant invention can be a surface
illumination with a conventional source for pulsed light of a suitable
wavelength, frequency and intensity, as described above, or can be a
surface illumination with a laser. The illumination can also be into the
body of a tumor, for example through optical fibers inserted thereinto.
The benzochlorinimines, other imines, metal complexes, and dimers of the
present invention can be used as discussed above for the treatment of
tumors, and they can also be used for the dissolution of plaques in blood
vessels, and for the treatment of topical conditions such as psoriasis,
fungal infections, acne, athletes foot, warts, papilloma and for the
sterilization of blood for transfusions, as will now be explained. While
the intravenus injection of the benzochlorins and the like has been
described, they can also be injected subcutaneously, intramuscularly or
intraperitoncally. Dosages can vary widely, but the in vivo test data
reported above indicate that the intravenous administration of up to 7 mg
per kg of body weight is safe. The benzochlorinimines and the like can be
formulated in lotions, suspensions or pastes for localized treatment,
e.g., of superficial tumors or skin disorders.
Various changes and modification can be made from the specific details of
the invention as described above without departing from the spirit and
scope thereof as defined in the appended claims.
Top